T-cell Therapy in Combination With Vemurafenib for Patients With BRAF Mutated Metastatic Melanoma

Trial Profile

T-cell Therapy in Combination With Vemurafenib for Patients With BRAF Mutated Metastatic Melanoma

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 09 Nov 2016

At a glance

  • Drugs Vemurafenib (Primary) ; Cyclophosphamide; Fludarabine; Interleukin-2; Tumour infiltrating lymphocytes
  • Indications Malignant melanoma
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 09 Feb 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top